About Morepen Laboratories Limited
Data last updated: 14 July 2026
Morepen Laboratories Limited is a public limited company based in Himachal Pradesh, Himachal Pradesh, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 01 December 1984, the company has been in operation for over 42 years.
Registered with ROC Himachal Pradesh under CIN L24231HP1984PLC006028. Listed on BSE: 500288 and NSE: MOREPENLAB.
Capital: an authorised share capital of ₹250 Cr and a paid-up capital of ₹109.58 Cr. Formerly known as Morepen Laboratories Private Limited. It is led by directors including Savita and Sushil Suri.
Last AGM: 06 September 2025. Financial statements filed for year ended 31 March 2025. Office: Village Morepen Nalagarh Road Near Baddi Distt Solan, Himachal Pradesh, Himachal Pradesh, India – 173205.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹1,805.69 Cr, a decline of 0.32% compared to the previous year. The net worth stands at ₹1,247.09 Cr (up 5.07% YoY). Total assets are valued at ₹1,936.12 Cr (up 8.89% YoY).
The company has a workforce of approximately 557 employees as per the latest available data. Its group structure includes 6 subsidiaries.
The company is associated with 1 brand - Morepen Laboratories. As per MCA filings, the company has open charges of ₹61.36 Cr and satisfied charges of ₹2,644.6 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website morepen.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressVillage Morepen Nalagarh Road Near Baddi Distt Solan, Himachal Pradesh, Himachal Pradesh, India – 173205
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Morepen Laboratories Limited
Morepen Laboratories Limited operates one associated brand: Morepen Laboratories. These brands represent Morepen Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| API, formulations, diagnostics, and FMHG products are manufactured and marketed. | morepen.com |
Business Activity of Morepen Laboratories Limited
Morepen Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Morepen Laboratories Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Morepen Laboratories Limited
Morepen Laboratories Limited is audited by S P Babuta & Associates (ICAI peer reviewed, certificate valid till 2028-06-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| S P Babuta & Associates (ICAI peer reviewed, certificate valid till 2028-06-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Morepen Laboratories Limited
Morepen Laboratories Limited is currently managed by 6 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Savita | Director | 22 Jun 2020 | 6 Years 2 Months | Current |
|
Sushil Suri
Also directs:
Bliss & Blue Ventures Llp, Shivalik Pesticides And Chemicals Pvt Ltd, Morepen Medipath Limited and 5 more
|
Managing Director | 20 Oct 2015 | 10 Years 10 Months | Current |
|
Sanjay Suri
Also directs:
Bliss & Blue Ventures Llp, Shivalik Pesticides And Chemicals Pvt Ltd, Morepen Medipath Limited and 5 more
|
Whole-Time Director | 13 Aug 2019 | 7 Years 0 Months | Current |
|
Praveen Kumar Dutt
Also directs:
Nexiris Global Private Limited, Si Infratel Private Limited
|
Director | 13 Aug 2019 | 7 Years 0 Months | Current |
|
Ranjit Khattar
Also directs:
Xpress Funding Advisors Llp, Dr. Morepen Limited, Eldeco Sohna Projects Limited and 5 more
|
Director | 12 Aug 2024 | 2 Years 0 Months | Current |
|
Sharad Jain
Also directs:
Dr. Morepen Limited
|
Director | 27 Aug 2024 | 1 Years 11 Months | Current |
Financials of Morepen Laboratories Limited FY 2026 filings available
Morepen Laboratories Limited reported revenue of ₹1,805.69 Cr (down 0.32% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,805.69 Cr | ₹1,811.58 Cr | ₹1,690.43 Cr | ₹1,417.53 Cr | ₹1,546.83 Cr | ₹1,188.06 Cr | ₹853.07 Cr |
| Other Income | ₹21.31 Cr | ₹18.36 Cr | ₹13.97 Cr | ₹6.13 Cr | ₹10.31 Cr | ₹12.07 Cr | ₹9.48 Cr |
| Total Income | ₹1,827.01 Cr | ₹1,829.94 Cr | ₹1,704.4 Cr | ₹1,423.66 Cr | ₹1,557.13 Cr | ₹1,200.13 Cr | ₹862.55 Cr |
| Cost of Materials Consumed | ₹1,043.11 Cr | ₹999.18 Cr | ₹883.31 Cr | ₹781.41 Cr | ₹797.13 Cr | ₹617.93 Cr | ₹413.22 Cr |
| Purchases of Stock-in-Trade | ₹82.46 Cr | ₹207.25 Cr | ₹177 Cr | ₹157.85 Cr | ₹262.23 Cr | ₹204.2 Cr | ₹154.43 Cr |
| Changes in Inventories | -₹2.15 Cr | -₹47.12 Cr | ₹2.11 Cr | ₹16.48 Cr | -₹10.04 Cr | -₹41.58 Cr | -₹10.23 Cr |
| Employee Benefit Expense | ₹232.74 Cr | ₹208.91 Cr | ₹181.47 Cr | ₹154.68 Cr | ₹164.25 Cr | ₹135.59 Cr | ₹109.91 Cr |
| Finance Costs | ₹16.41 Cr | ₹8.34 Cr | ₹3.71 Cr | ₹1.98 Cr | -₹7.37 Cr | ₹1.79 Cr | ₹1.98 Cr |
| Depreciation & Amortisation | ₹36.43 Cr | ₹28.98 Cr | ₹33.47 Cr | ₹27.93 Cr | ₹27.64 Cr | ₹30.28 Cr | ₹36.91 Cr |
| Other Expenses | ₹323.91 Cr | ₹269.28 Cr | ₹287.92 Cr | ₹227.57 Cr | ₹196.59 Cr | ₹153.4 Cr | ₹117.23 Cr |
| Total Expenses | ₹1,732.91 Cr | ₹1,674.83 Cr | ₹1,568.99 Cr | ₹1,367.91 Cr | ₹1,430.43 Cr | ₹1,101.61 Cr | ₹823.44 Cr |
| Profit Before Exceptional Items & Tax | ₹94.09 Cr | ₹155.11 Cr | ₹135.42 Cr | ₹55.76 Cr | ₹126.7 Cr | ₹98.51 Cr | ₹39.11 Cr |
| Exceptional Items | ₹25.83 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹119.92 Cr | ₹155.11 Cr | ₹135.42 Cr | ₹55.76 Cr | ₹126.7 Cr | ₹98.51 Cr | ₹39.11 Cr |
| Total Tax Expense | ₹24.27 Cr | ₹37.09 Cr | ₹38.8 Cr | ₹17.08 Cr | ₹25.02 Cr | ₹1.42 Cr | ₹5.53 Cr |
| Net Profit | ₹94.88 Cr | ₹118.02 Cr | ₹96.16 Cr | ₹38.68 Cr | ₹101.68 Cr | ₹97.09 Cr | ₹33.58 Cr |
| attributable to Owners | ₹0 | ₹0 | ₹0 | - | - | - | ₹0 |
| attributable to NCI | ₹0 | ₹0 | ₹0 | - | - | - | ₹0 |
| Other Comprehensive Income | ₹6.19 Cr | ₹25.37 Lakh | -₹1.84 Cr | -₹1.48 Cr | -₹37.1 Lakh | -₹14.72 Lakh | -₹2.61 Cr |
| Total Comprehensive Income | ₹101.07 Cr | ₹118.27 Cr | ₹94.32 Cr | ₹37.19 Cr | ₹101.31 Cr | ₹96.94 Cr | ₹30.97 Cr |
| EBITDA (computed) | ₹146.94 Cr | ₹192.43 Cr | ₹172.6 Cr | ₹85.67 Cr | ₹146.98 Cr | ₹130.58 Cr | ₹78 Cr |
| Basic EPS | ₹1.73 | ₹2.20 | ₹1.88 | ₹0.77 | ₹2.26 | ₹2.16 | ₹0.75 |
| Diluted EPS | ₹1.73 | ₹2.20 | ₹1.88 | ₹0.77 | ₹1.96 | ₹2.15 | ₹0.75 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,936.12 Cr | ₹1,778.1 Cr | ₹1,293.21 Cr | ₹1,110.5 Cr |
| Non-current Assets | ₹772.51 Cr | ₹618.73 Cr | ₹404.16 Cr | ₹354.33 Cr |
| Current Assets | ₹1,163.61 Cr | ₹1,159.37 Cr | ₹889.04 Cr | ₹756.16 Cr |
| Property, Plant & Equipment | ₹381.16 Cr | ₹316.51 Cr | ₹213.2 Cr | ₹167 Cr |
| Inventories | ₹271.83 Cr | ₹299.97 Cr | ₹248.59 Cr | ₹228.89 Cr |
| Trade Receivables | ₹333.14 Cr | ₹324.76 Cr | ₹324.94 Cr | ₹263.25 Cr |
| Cash & Equivalents | ₹31.19 Cr | ₹27.38 Cr | ₹16.95 Cr | ₹21.67 Cr |
| Equity (Net Worth) | ₹1,247.09 Cr | ₹1,186.96 Cr | ₹847.23 Cr | ₹752.45 Cr |
| Equity Share Capital | ₹109.58 Cr | ₹109.58 Cr | ₹102.23 Cr | ₹102.23 Cr |
| Borrowings (Non-current) | ₹133.6 Cr | ₹25.76 Cr | ₹3.36 Cr | ₹93.35 Lakh |
| Borrowings (Current) | ₹61.09 Cr | ₹53.63 Cr | ₹25.64 Cr | ₹24.23 Cr |
| Total Debt (computed) | ₹194.69 Cr | ₹79.39 Cr | ₹29 Cr | ₹25.16 Cr |
| Current Liabilities | ₹490.3 Cr | ₹500.65 Cr | ₹402.04 Cr | ₹321.16 Cr |
| Total Liabilities | ₹689.03 Cr | ₹591.14 Cr | ₹445.98 Cr | ₹358.05 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹32.64 Cr | ₹32.06 Cr | ₹73.37 Cr | -₹91.17 Cr | -₹57.76 Cr |
| Investing Cash Flow | -₹123.42 Cr | -₹321.51 Cr | -₹83.3 Cr | -₹46.51 Cr | -₹31.68 Cr |
| Financing Cash Flow | ₹97.4 Cr | ₹299.89 Cr | ₹5.2 Cr | ₹143.54 Cr | ₹63.85 Cr |
| Capital Expenditure | ₹85.52 Cr | ₹124.03 Cr | ₹71.38 Cr | ₹35.62 Cr | ₹45.45 Cr |
| Free Cash Flow (computed) | -₹52.88 Cr | -₹91.98 Cr | ₹1.99 Cr | -₹126.79 Cr | -₹103.2 Cr |
| Dividends Paid | ₹10.86 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹6.62 Cr | ₹10.44 Cr | -₹4.72 Cr | ₹5.86 Cr | -₹25.58 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹484.72 Cr | ₹484.16 Cr | ₹411.58 Cr | ₹425.24 Cr | ₹465.85 Cr | ₹452.78 Cr | ₹437.73 Cr | ₹455.22 Cr | ₹423.07 Cr | ₹444.55 Cr | ₹421.77 Cr | ₹401.04 Cr |
| Other Income | ₹8.46 Cr | ₹3.81 Cr | ₹4.64 Cr | ₹4.41 Cr | ₹4.61 Cr | ₹5.34 Cr | ₹4.99 Cr | ₹3.43 Cr | ₹4.24 Cr | ₹4.07 Cr | ₹3.24 Cr | ₹2.42 Cr |
| Total Income | ₹493.18 Cr | ₹487.97 Cr | ₹416.21 Cr | ₹429.65 Cr | ₹470.46 Cr | ₹458.12 Cr | ₹442.71 Cr | ₹458.64 Cr | ₹427.32 Cr | ₹448.62 Cr | ₹425.01 Cr | ₹403.46 Cr |
| Cost of Materials Consumed | ₹290.58 Cr | ₹294.19 Cr | ₹220.63 Cr | ₹237.71 Cr | ₹268.43 Cr | ₹239.52 Cr | ₹256.22 Cr | ₹235.01 Cr | ₹220.26 Cr | ₹235.6 Cr | ₹227.36 Cr | ₹200.08 Cr |
| Purchases of Stock-in-Trade | ₹17.67 Cr | ₹15.77 Cr | ₹31.98 Cr | ₹17.04 Cr | ₹71.31 Cr | ₹40.67 Cr | ₹39.29 Cr | ₹55.97 Cr | ₹30.08 Cr | ₹45.6 Cr | ₹43.61 Cr | ₹57.71 Cr |
| Changes in Inventories | -₹8.72 Cr | -₹12.62 Cr | ₹11.58 Cr | ₹7.62 Cr | -₹23.98 Cr | ₹10.45 Cr | -₹25.41 Cr | -₹8.18 Cr | ₹6.18 Cr | -₹9.16 Cr | ₹1.8 Cr | ₹3.29 Cr |
| Employee Benefit Expense | ₹58.76 Cr | ₹62.09 Cr | ₹56.65 Cr | ₹55.24 Cr | ₹57.01 Cr | ₹54.28 Cr | ₹49.67 Cr | ₹47.96 Cr | ₹47.94 Cr | ₹46.8 Cr | ₹43.32 Cr | ₹43.41 Cr |
| Finance Costs | ₹3.88 Cr | ₹4.32 Cr | ₹4.18 Cr | ₹4.04 Cr | ₹4.67 Cr | ₹1.34 Cr | ₹1.18 Cr | ₹1.15 Cr | ₹79.8 Lakh | ₹2.17 Cr | ₹45.79 Lakh | ₹28.27 Lakh |
| Depreciation & Amortisation | ₹5.75 Cr | ₹10.38 Cr | ₹11.28 Cr | ₹9.03 Cr | ₹16.47 Cr | ₹4.93 Cr | ₹1.86 Cr | ₹5.73 Cr | ₹9.62 Cr | ₹8.45 Cr | ₹7.69 Cr | ₹7.71 Cr |
| Other Expenses | ₹101.99 Cr | ₹78.42 Cr | ₹60.04 Cr | ₹83.47 Cr | ₹50.85 Cr | ₹71.71 Cr | ₹73.89 Cr | ₹72.83 Cr | ₹70.23 Cr | ₹75.15 Cr | ₹72.09 Cr | ₹70.45 Cr |
| Total Expenses | ₹469.89 Cr | ₹452.55 Cr | ₹396.34 Cr | ₹414.13 Cr | ₹444.75 Cr | ₹422.91 Cr | ₹396.69 Cr | ₹410.48 Cr | ₹385.11 Cr | ₹404.6 Cr | ₹396.32 Cr | ₹382.94 Cr |
| Profit Before Exceptional Items & Tax | ₹23.29 Cr | ₹35.42 Cr | ₹19.87 Cr | ₹15.52 Cr | ₹25.71 Cr | ₹35.21 Cr | ₹46.02 Cr | ₹48.17 Cr | ₹42.2 Cr | ₹44.02 Cr | ₹28.68 Cr | ₹20.51 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹25.83 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹23.29 Cr | ₹35.42 Cr | ₹45.69 Cr | ₹15.52 Cr | ₹25.71 Cr | ₹35.21 Cr | ₹46.02 Cr | ₹48.17 Cr | ₹42.2 Cr | ₹44.02 Cr | ₹28.68 Cr | ₹20.51 Cr |
| Total Tax Expense | ₹7.59 Cr | ₹7.93 Cr | ₹4.65 Cr | ₹4.11 Cr | ₹5.4 Cr | ₹8.52 Cr | ₹11.17 Cr | ₹12 Cr | ₹13.46 Cr | ₹12.03 Cr | ₹7.43 Cr | ₹5.88 Cr |
| Net Profit | ₹15.74 Cr | ₹27.51 Cr | ₹40.87 Cr | ₹10.75 Cr | ₹20.32 Cr | ₹26.69 Cr | ₹34.85 Cr | ₹36.17 Cr | ₹28.28 Cr | ₹31.99 Cr | ₹21.26 Cr | ₹14.63 Cr |
| attributable to Owners | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | - | - | - | ₹0 | - | ₹0 | - |
| attributable to NCI | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | - | - | - | ₹0 | - | ₹0 | - |
| Other Comprehensive Income | ₹6.36 Cr | ₹58.81 Lakh | -₹1.35 Cr | ₹59 Lakh | -₹80.34 Lakh | -₹40.36 Lakh | -₹1.11 Cr | ₹2.57 Cr | -₹2.03 Cr | -₹46,000 | -₹81.52 Lakh | ₹1.01 Cr |
| Total Comprehensive Income | ₹22.11 Cr | ₹28.1 Cr | ₹39.52 Cr | ₹11.34 Cr | ₹19.51 Cr | ₹26.28 Cr | ₹33.74 Cr | ₹38.74 Cr | ₹26.25 Cr | ₹31.99 Cr | ₹20.44 Cr | ₹15.65 Cr |
| EBITDA (computed) | ₹32.91 Cr | ₹50.12 Cr | ₹35.33 Cr | ₹28.58 Cr | ₹46.85 Cr | ₹41.48 Cr | ₹49.06 Cr | ₹55.05 Cr | ₹52.62 Cr | ₹54.64 Cr | ₹36.83 Cr | ₹28.51 Cr |
| Basic EPS | ₹0.28 | ₹0.50 | ₹0.75 | ₹0.20 | ₹0.35 | ₹0.49 | ₹0.65 | ₹0.71 | ₹0.54 | ₹0.63 | ₹0.42 | ₹0.29 |
| Diluted EPS | ₹0.28 | ₹0.50 | ₹0.75 | ₹0.20 | ₹0.35 | ₹0.49 | ₹0.65 | ₹0.71 | ₹0.54 | ₹0.63 | ₹0.42 | ₹0.29 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,681.2 Cr | ₹1,554.54 Cr | ₹1,537.59 Cr | ₹1,338.88 Cr | ₹1,449.27 Cr | ₹1,112.42 Cr | ₹791.99 Cr |
| Other Income | ₹21.5 Cr | ₹15.72 Cr | ₹12.57 Cr | ₹5.76 Cr | ₹10.24 Cr | ₹11.77 Cr | ₹9.42 Cr |
| Total Income | ₹1,702.69 Cr | ₹1,570.25 Cr | ₹1,550.16 Cr | ₹1,344.64 Cr | ₹1,459.5 Cr | ₹1,124.2 Cr | ₹801.4 Cr |
| Cost of Materials Consumed | ₹1,043.11 Cr | ₹999.18 Cr | ₹883.31 Cr | ₹781.41 Cr | ₹797.13 Cr | ₹617.93 Cr | ₹413.22 Cr |
| Purchases of Stock-in-Trade | ₹15.02 Cr | ₹20.81 Cr | ₹61.84 Cr | ₹105.07 Cr | ₹191.68 Cr | ₹160.67 Cr | ₹115.45 Cr |
| Changes in Inventories | ₹3.23 Cr | -₹44.36 Cr | ₹5.13 Cr | ₹16.54 Cr | ₹1.74 Cr | -₹41.98 Cr | -₹7.58 Cr |
| Employee Benefit Expense | ₹206.28 Cr | ₹177.22 Cr | ₹160.28 Cr | ₹146.19 Cr | ₹150 Cr | ₹123.2 Cr | ₹98.07 Cr |
| Finance Costs | ₹16.1 Cr | ₹7.1 Cr | ₹3.51 Cr | ₹1.98 Cr | -₹7.37 Cr | ₹1.79 Cr | ₹1.97 Cr |
| Depreciation & Amortisation | ₹29.31 Cr | ₹24.44 Cr | ₹21.9 Cr | ₹18.01 Cr | ₹21.19 Cr | ₹28.11 Cr | ₹34.43 Cr |
| Other Expenses | ₹301.48 Cr | ₹248.27 Cr | ₹265.22 Cr | ₹212.4 Cr | ₹179.58 Cr | ₹140.23 Cr | ₹108.36 Cr |
| Total Expenses | ₹1,614.52 Cr | ₹1,432.67 Cr | ₹1,401.18 Cr | ₹1,281.6 Cr | ₹1,333.96 Cr | ₹1,029.95 Cr | ₹763.92 Cr |
| Profit Before Exceptional Items & Tax | ₹88.17 Cr | ₹137.59 Cr | ₹148.98 Cr | ₹63.04 Cr | ₹125.54 Cr | ₹94.25 Cr | ₹37.48 Cr |
| Exceptional Items | ₹1.1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹89.26 Cr | ₹137.59 Cr | ₹148.98 Cr | ₹63.04 Cr | ₹125.54 Cr | ₹94.25 Cr | ₹37.48 Cr |
| Total Tax Expense | ₹23.21 Cr | ₹36.01 Cr | ₹38.04 Cr | ₹16.8 Cr | ₹24.48 Cr | ₹0 | ₹5.15 Cr |
| Net Profit | ₹66.06 Cr | ₹101.58 Cr | ₹110.94 Cr | ₹46.24 Cr | ₹101.06 Cr | ₹94.25 Cr | ₹32.33 Cr |
| Other Comprehensive Income | ₹6.06 Cr | ₹17.23 Lakh | -₹2.03 Cr | -₹1.45 Cr | -₹36.85 Lakh | -₹27.26 Lakh | -₹2.54 Cr |
| Total Comprehensive Income | ₹72.11 Cr | ₹101.75 Cr | ₹108.91 Cr | ₹44.8 Cr | ₹100.69 Cr | ₹93.98 Cr | ₹29.79 Cr |
| EBITDA (computed) | ₹133.57 Cr | ₹169.13 Cr | ₹174.38 Cr | ₹83.03 Cr | ₹139.37 Cr | ₹124.15 Cr | ₹73.88 Cr |
| Basic EPS | ₹1.21 | ₹1.90 | ₹2.17 | ₹0.92 | ₹2.25 | ₹2.10 | ₹0.72 |
| Diluted EPS | ₹1.21 | ₹1.90 | ₹2.17 | ₹0.92 | ₹1.94 | ₹2.09 | ₹0.72 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,907.66 Cr | ₹1,721.2 Cr | ₹1,279.31 Cr | ₹1,105.54 Cr |
| Non-current Assets | ₹669.19 Cr | ₹614.42 Cr | ₹436.4 Cr | ₹374.69 Cr |
| Current Assets | ₹1,238.47 Cr | ₹1,106.78 Cr | ₹842.91 Cr | ₹730.85 Cr |
| Property, Plant & Equipment | ₹307.52 Cr | ₹315.89 Cr | ₹212.44 Cr | ₹166.09 Cr |
| Inventories | ₹154.26 Cr | ₹286.39 Cr | ₹220.15 Cr | ₹211.35 Cr |
| Trade Receivables | ₹333.19 Cr | ₹293.75 Cr | ₹316.89 Cr | ₹255.47 Cr |
| Cash & Equivalents | ₹10.57 Cr | ₹24.43 Cr | ₹15.3 Cr | ₹21.26 Cr |
| Equity (Net Worth) | ₹1,242.76 Cr | ₹1,181.5 Cr | ₹889.02 Cr | ₹780.11 Cr |
| Equity Share Capital | ₹109.58 Cr | ₹109.58 Cr | ₹102.23 Cr | ₹102.23 Cr |
| Borrowings (Non-current) | ₹132.86 Cr | ₹25.76 Cr | ₹3.36 Cr | ₹93.35 Lakh |
| Borrowings (Current) | ₹60.73 Cr | ₹53.2 Cr | ₹24.83 Cr | ₹24.23 Cr |
| Total Debt (computed) | ₹193.59 Cr | ₹78.96 Cr | ₹28.19 Cr | ₹25.16 Cr |
| Current Liabilities | ₹346.29 Cr | ₹461.56 Cr | ₹352.64 Cr | ₹290.98 Cr |
| Total Liabilities | ₹664.9 Cr | ₹539.7 Cr | ₹390.28 Cr | ₹325.43 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹20.47 Cr | ₹29.08 Cr | ₹77.36 Cr | -₹102.12 Cr | -₹66.38 Cr |
| Investing Cash Flow | -₹119.02 Cr | -₹280.42 Cr | -₹83.6 Cr | -₹36.2 Cr | -₹22.64 Cr |
| Financing Cash Flow | ₹97.12 Cr | ₹260.47 Cr | ₹28.22 Lakh | ₹144.2 Cr | ₹63.93 Cr |
| Capital Expenditure | ₹83.76 Cr | ₹123.95 Cr | ₹71.23 Cr | ₹35.55 Cr | ₹45.16 Cr |
| Free Cash Flow (computed) | -₹63.29 Cr | -₹94.88 Cr | ₹6.13 Cr | -₹137.66 Cr | -₹111.54 Cr |
| Dividends Paid | ₹10.86 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹1.43 Cr | ₹9.12 Cr | -₹5.96 Cr | ₹5.88 Cr | -₹25.09 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹462.81 Cr | ₹457.57 Cr | ₹369.53 Cr | ₹391.28 Cr | ₹381.94 Cr | ₹403.25 Cr | ₹383.7 Cr | ₹385.64 Cr | ₹392.6 Cr | ₹394.63 Cr | ₹381.26 Cr | ₹369.1 Cr |
| Other Income | ₹8.82 Cr | ₹3.93 Cr | ₹4.65 Cr | ₹4.09 Cr | ₹3.14 Cr | ₹4.87 Cr | ₹4.63 Cr | ₹3.07 Cr | ₹3.99 Cr | ₹3.66 Cr | ₹2.84 Cr | ₹2.08 Cr |
| Total Income | ₹471.63 Cr | ₹461.5 Cr | ₹374.18 Cr | ₹395.38 Cr | ₹385.08 Cr | ₹408.13 Cr | ₹388.33 Cr | ₹388.72 Cr | ₹396.59 Cr | ₹398.29 Cr | ₹384.1 Cr | ₹371.19 Cr |
| Cost of Materials Consumed | ₹290.58 Cr | ₹294.19 Cr | ₹220.63 Cr | ₹237.71 Cr | ₹268.43 Cr | ₹239.52 Cr | ₹256.22 Cr | ₹235.01 Cr | ₹220.26 Cr | ₹235.6 Cr | ₹227.36 Cr | ₹200.08 Cr |
| Purchases of Stock-in-Trade | ₹5 Cr | ₹1.62 Cr | ₹7.09 Cr | ₹1.31 Cr | ₹5.77 Cr | ₹5.77 Cr | ₹3.47 Cr | ₹5.81 Cr | ₹2.33 Cr | ₹9 Cr | ₹17.89 Cr | ₹32.62 Cr |
| Changes in Inventories | -₹5.52 Cr | -₹10.81 Cr | ₹9.73 Cr | ₹9.83 Cr | -₹21.46 Cr | ₹12.41 Cr | -₹26.09 Cr | -₹9.22 Cr | ₹11.3 Cr | -₹9.24 Cr | ₹45.1 Lakh | ₹2.62 Cr |
| Employee Benefit Expense | ₹54.37 Cr | ₹55.61 Cr | ₹49.61 Cr | ₹46.69 Cr | ₹48.15 Cr | ₹46.3 Cr | ₹42.84 Cr | ₹39.94 Cr | ₹40.17 Cr | ₹40.32 Cr | ₹38.73 Cr | ₹41.07 Cr |
| Finance Costs | ₹3.87 Cr | ₹4.31 Cr | ₹4.11 Cr | ₹3.81 Cr | ₹3.74 Cr | ₹1.27 Cr | ₹1.05 Cr | ₹1.04 Cr | ₹72.77 Lakh | ₹2.04 Cr | ₹45.49 Lakh | ₹28.27 Lakh |
| Depreciation & Amortisation | ₹63.23 Lakh | ₹10.09 Cr | ₹10.7 Cr | ₹7.88 Cr | ₹12.25 Cr | ₹4.81 Cr | ₹3.79 Cr | ₹3.59 Cr | ₹6.69 Cr | ₹5.51 Cr | ₹4.81 Cr | ₹4.89 Cr |
| Other Expenses | ₹95.07 Cr | ₹75.07 Cr | ₹54.54 Cr | ₹76.8 Cr | ₹50.9 Cr | ₹67.68 Cr | ₹64.19 Cr | ₹65.5 Cr | ₹62.4 Cr | ₹67.85 Cr | ₹67.06 Cr | ₹67.9 Cr |
| Total Expenses | ₹444 Cr | ₹430.08 Cr | ₹356.41 Cr | ₹384.02 Cr | ₹367.78 Cr | ₹377.75 Cr | ₹345.48 Cr | ₹341.67 Cr | ₹343.88 Cr | ₹351.07 Cr | ₹356.76 Cr | ₹349.47 Cr |
| Profit Before Exceptional Items & Tax | ₹27.63 Cr | ₹31.42 Cr | ₹17.77 Cr | ₹11.35 Cr | ₹17.3 Cr | ₹30.38 Cr | ₹42.86 Cr | ₹47.05 Cr | ₹52.71 Cr | ₹47.22 Cr | ₹27.33 Cr | ₹21.71 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹1.1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹27.63 Cr | ₹31.42 Cr | ₹18.86 Cr | ₹11.35 Cr | ₹17.3 Cr | ₹30.38 Cr | ₹42.86 Cr | ₹47.05 Cr | ₹52.71 Cr | ₹47.22 Cr | ₹27.33 Cr | ₹21.71 Cr |
| Total Tax Expense | ₹7.5 Cr | ₹7.93 Cr | ₹4.49 Cr | ₹3.29 Cr | ₹5.39 Cr | ₹7.69 Cr | ₹10.93 Cr | ₹12 Cr | ₹12.75 Cr | ₹12.02 Cr | ₹7.41 Cr | ₹5.86 Cr |
| Net Profit | ₹20.12 Cr | ₹23.5 Cr | ₹14.38 Cr | ₹8.06 Cr | ₹11.91 Cr | ₹22.69 Cr | ₹31.93 Cr | ₹35.05 Cr | ₹39.96 Cr | ₹35.2 Cr | ₹19.92 Cr | ₹15.85 Cr |
| Other Comprehensive Income | ₹6.05 Cr | ₹60.39 Lakh | -₹1.16 Cr | ₹56.77 Lakh | -₹79.72 Lakh | -₹42.71 Lakh | -₹1.16 Cr | ₹2.56 Cr | -₹2.23 Cr | -₹1 Lakh | -₹87.92 Lakh | ₹1.09 Cr |
| Total Comprehensive Income | ₹26.17 Cr | ₹24.1 Cr | ₹13.21 Cr | ₹8.63 Cr | ₹11.11 Cr | ₹22.26 Cr | ₹30.77 Cr | ₹37.61 Cr | ₹37.73 Cr | ₹35.19 Cr | ₹19.04 Cr | ₹16.94 Cr |
| EBITDA (computed) | ₹32.13 Cr | ₹45.82 Cr | ₹32.58 Cr | ₹23.04 Cr | ₹33.3 Cr | ₹36.45 Cr | ₹47.7 Cr | ₹51.68 Cr | ₹60.12 Cr | ₹54.77 Cr | ₹32.6 Cr | ₹26.89 Cr |
| Basic EPS | ₹0.37 | ₹0.43 | ₹0.26 | ₹0.15 | ₹0.20 | ₹0.41 | ₹0.60 | ₹0.69 | ₹0.78 | ₹0.69 | ₹0.39 | ₹0.31 |
| Diluted EPS | ₹0.37 | ₹0.43 | ₹0.26 | ₹0.15 | ₹0.20 | ₹0.41 | ₹0.60 | ₹0.69 | ₹0.78 | ₹0.69 | ₹0.39 | ₹0.31 |
Shareholding Pattern of Morepen Laboratories Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 35.65%, foreign institutional investors hold 1.58%, domestic institutional investors hold 1.25%, retail and other public shareholders hold 61.50% of Morepen Laboratories Limited. The company had 447,286 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 35.65% | 35.65% | 35.65% | 35.65% | 35.65% | 35.65% |
| Public | 64.35% | 64.35% | 64.35% | 64.35% | 64.35% | 64.35% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 35.65% | 35.65% | 38.22% | 38.22% | 38.38% | 34.54% | 34.54% | 34.54% | 34.54% | 34.54% | 34.54% |
| Public | 64.35% | 64.35% | 61.78% | 61.78% | 61.62% | 65.46% | 65.46% | 65.46% | 65.46% | 65.46% | 65.46% |
| Promoter change (YoY, %pts) | +0.00 | -2.57 | +0.00 | -0.16 | +3.84 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | - |
Board & Governance of Morepen Laboratories Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Morepen Laboratories Limited has 6 directors - 4 independent and 2 executive. The board is chaired by SUSHIL SURI.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| SUSHIL SURI | Executive Director · MD · Chairperson | 1992-04-10 | 1 |
| SANJAY SURI | Executive Director | 2019-08-13 | 1 |
| PRAVEEN KUMAR DUTT | Non-Executive - Independent Director | 2019-08-13 | 1 |
| RANJIT KHATTAR | Non-Executive - Independent Director | 2024-08-12 | 1 |
| SHARAD JAIN | Non-Executive - Independent Director | 2024-08-27 | 1 |
| SAVITA | Non-Executive - Independent Director | 2020-06-22 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | PRAVEEN KUMAR DUTT (Chairperson), RANJIT KHATTAR, SHARAD JAIN |
| Nomination and remuneration committee | PRAVEEN KUMAR DUTT (Chairperson), RANJIT KHATTAR, SHARAD JAIN |
| Stakeholders Relationship Committee | PRAVEEN KUMAR DUTT (Chairperson), SUSHIL SURI, SAVITA |
| Risk Management Committee | PRAVEEN KUMAR DUTT (Chairperson), SUSHIL SURI, RANJIT KHATTAR |
| Corporate Social Responsibility Committee | SUSHIL SURI (Chairperson), PRAVEEN KUMAR DUTT, SAVITA |
| Finance Committee | SUSHIL SURI (Chairperson), PRAVEEN KUMAR DUTT, SANJAY SURI |
| QIP Issue Committee | PRAVEEN KUMAR DUTT (Chairperson), RANJIT KHATTAR, SHARAD JAIN |
Group Structure of Morepen Laboratories Limited
Morepen Laboratories Limited has 6 subsidiary companies. This group structure data is as of FY 2025. The corporate group structure reflects Morepen Laboratories Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Morepen Rx Limited | U21001HP2023PLC009940 | - |
| Dr. Morepen Limited | U24232DL2001PLC111636 | - |
| Total Care Limited | U24246DL2000PLC105296 | - |
| Morepen Medipath Limited | U32509HP2025PLC011337 | - |
| Morepen Devices Limited | U33112HP2021PLC008798 | - |
| Quick Med Private Limited | U46497HR2025PTC129787 | - |
Showing major subsidiaries. Total: 6.
Charges & Borrowings of Morepen Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Jan 2026 | Others | ₹31 Lakh | Open |
| 28 Dec 2025 | Others | ₹1.22 Cr | Open |
| 23 May 2025 | Others | ₹50 Cr | Open |
| 22 Apr 2025 | Others | ₹56.5 Lakh | Open |
| 29 Mar 2025 | Others | ₹28.4 Lakh | Open |
Total charge records: 120 View all charges
Employees and EPFO Compliance at Morepen Laboratories Limited
Morepen Laboratories Limited has a workforce of 557 employees as of Sep 23, 2025.
Employee and EPFO history for Morepen Laboratories Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Morepen Laboratories Limited
GST registrations and filing compliance for Morepen Laboratories Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Morepen Laboratories Limited
Credit ratings, litigation, and regulatory alerts for Morepen Laboratories Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Morepen Laboratories Limited
MSME payment history for Morepen Laboratories Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Morepen Laboratories Limited
Corporate group structure for Morepen Laboratories Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Morepen Laboratories Limited
MCA filings and documents for Morepen Laboratories Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Morepen Laboratories Limited
Recent News on Morepen Laboratories Limited
Frequently Asked Questions about Morepen Laboratories Limited
Morepen Laboratories Limited is an active public limited company in the pharma sector based in Himachal Pradesh, Himachal Pradesh, India. It was incorporated on 01 December 1984 (42+ years old) and is registered under CIN L24231HP1984PLC006028. Listed on BSE: 500288 and NSE: MOREPENLAB. The company has 557 employees.
Morepen Laboratories Limited reported revenue of ₹1,805.69 Cr for FY 2026 (down 0.32% YoY) based on consolidated NSE filings.
The current directors of Morepen Laboratories Limited are:
- Savita - Director
- Sushil Suri - Managing Director
- Sanjay Suri - Whole-Time Director
- Praveen Kumar Dutt - Director
- Ranjit Khattar - Director
- Sharad Jain - Director
The primary industry of Morepen Laboratories Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Morepen Laboratories Limited is listed on both BSE (code: 500288) and NSE (symbol: MOREPENLAB).
Morepen Laboratories Limited can be reached at the registered office: Village Morepen Nalagarh Road Near Baddi Distt Solan, Himachal Pradesh, Himachal Pradesh, India – 173205, or through the website morepen.com.